Technical Analysis for CYCCP - Cyclacel Pharmaceuticals, Inc. - 6% Convertible Preferred Stock
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Crossed Above 20 DMA | Bullish | 0.00% | |
Outside Day | Range Expansion | 0.00% | |
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 2.74% | |
Narrow Range Bar | Range Contraction | 2.74% | |
Inside Day | Range Contraction | 2.74% | |
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 4.60% | |
Narrow Range Bar | Range Contraction | 4.60% | |
Outside Day | Range Expansion | 4.60% | |
Wide Bands | Range Expansion | 4.60% | |
MACD Bullish Signal Line Cross | Bullish | 2.74% |
Alert | Time |
---|---|
Rose Above 20 DMA | about 19 hours ago |
Rose Above Previous Day's High | about 19 hours ago |
Outside Day | about 19 hours ago |
Non-ADX 1,2,3,4 Bearish Retracement Entry | about 19 hours ago |
Fell Below Previous Day's Low | about 19 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 11/11/2024
Cyclacel Pharmaceuticals, Inc. - 6% Convertible Preferred Stock Description
Cyclacel Pharmaceuticals, Inc., a development-stage biopharmaceutical company, engages in the development and commercialization of mechanism-targeted drugs to treat human cancers and other serious diseases. The company's oncology development programs include its lead candidate, sapacitabine, which is in Phase III study that interferes with DNA synthesis and repair by causing single-strand DNA breaks that could induce arrest of the cell division cycle at the G2/M checkpoint; and second drug candidate, seliciclib, which is an orally-available CDK inhibitor that selectively inhibits a spectrum of enzyme targets, including CDK2/E, CDK2/A, CDK7, and CDK9 that are central to the process of cell division and cell cycle control. Its oncology development programs also comprise Plk1 Inhibitors, which is in preclinical stage for the treatment of cancer; CYC065, an orally-available 2nd generation inhibitor of CDK-2, -5, and -9 that helps in cancer cell growth, metastatic spread, and DNA damage repair; and Sapacitabine + Seliciclib, which is in Phase I trial for the treatment of cancer. The company's non-oncology programs include Cell Cycle Inhibitors, which completed Phase I trial for the treatment of autoimmune and inflammatory diseases. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Biology Treatment Of Cancer Cell Biology Inflammatory Diseases Cancer Cell Autoimmune And Inflammatory Disease Human Cancers Cell Cycle Cyclacel Cyclin Dependent Kinase Dna Synthesis PLK1 Cdk Inhibitor Cell Cycle Checkpoint Cyclin Dependent Kinase 2 Sapacitabine Seliciclib
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 22.2 |
52 Week Low | 5.2096 |
Average Volume | 2,205 |
200-Day Moving Average | 12.44 |
50-Day Moving Average | 8.65 |
20-Day Moving Average | 7.33 |
10-Day Moving Average | 7.17 |
Average True Range | 0.59 |
RSI (14) | 46.81 |
ADX | 17.11 |
+DI | 27.23 |
-DI | 33.99 |
Chandelier Exit (Long, 3 ATRs) | 7.09 |
Chandelier Exit (Short, 3 ATRs) | 7.83 |
Upper Bollinger Bands | 8.19 |
Lower Bollinger Band | 6.48 |
Percent B (%b) | 0.6 |
BandWidth | 23.30 |
MACD Line | -0.40 |
MACD Signal Line | -0.49 |
MACD Histogram | 0.0928 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 7.95 | ||||
Resistance 3 (R3) | 7.90 | 7.70 | 7.88 | ||
Resistance 2 (R2) | 7.70 | 7.59 | 7.73 | 7.85 | |
Resistance 1 (R1) | 7.60 | 7.51 | 7.65 | 7.65 | 7.82 |
Pivot Point | 7.40 | 7.40 | 7.43 | 7.43 | 7.40 |
Support 1 (S1) | 7.30 | 7.29 | 7.35 | 7.35 | 7.18 |
Support 2 (S2) | 7.10 | 7.21 | 7.13 | 7.15 | |
Support 3 (S3) | 7.00 | 7.10 | 7.13 | ||
Support 4 (S4) | 7.05 |